What is RDD Pharma?
RDD Pharma operates as a specialty pharmaceutical entity dedicated to the rapid development and commercialization of therapeutics for underserved medical conditions, including fecal incontinence and pruritus ani. The company distinguishes itself by utilizing a proprietary drug-delivery technology combined with the repurposing of already approved pharmaceutical compounds. This strategic approach allows RDD Pharma to navigate a shorter regulatory pathway compared to traditional New Chemical Entities, effectively positioning the firm in a lucrative market niche between generic manufacturers and large-scale pharmaceutical innovators. With a pipeline that includes preclinical assets for radiation proctitis, the company is systematically building a portfolio of high-value, clinically validated solutions expected to reach commercialization within a 2 to 6-year horizon.
How much funding has RDD Pharma raised?
RDD Pharma has raised a total of $17.9M across 3 funding rounds:
Series A
$7.2M
Grant
$1.3M
Series B
$9.5M
Series A (2012): $7.2M with participation from Orbimed
Grant (2017): $1.3M led by Department of Defense
Series B (2017): $9.5M supported by Pharmascience, Inc and OrbiMed
Key Investors in RDD Pharma
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Pharmascience, Inc
Founded in 1983 and headquartered in Montreal, Pharmascience is a prominent manufacturer of generic and branded pharmaceutical products with a global reach.
Department of Defense
The U.S. Department of Defense is the federal executive department responsible for national security and the oversight of advanced technological development and research initiatives.
What's next for RDD Pharma?
With the infusion of recent capital, RDD Pharma is well-positioned to advance its preclinical and clinical-stage assets through the regulatory pipeline. The company's strategic focus remains on optimizing its proprietary delivery platforms to enhance the efficacy of existing molecules. As the firm moves toward commercialization, it will likely prioritize scaling its operational infrastructure and strengthening its market presence in the gastrointestinal therapeutic space. Investors and industry observers will be monitoring the company's ability to maintain its accelerated development timeline while navigating the complexities of late-stage clinical trials and subsequent market entry. The ongoing support from specialized healthcare investors suggests a high degree of confidence in the firm's ability to deliver tangible clinical outcomes and long-term shareholder value.
See full RDD Pharma company page
